TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06221748: A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer an

Sponsor: RemeGen Co., Ltd. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$16,514,652

Rescue Site Savings

+$10,878,252

Unlock Full NCT06221748 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06221748 Rescue Dossier →